Mengyu Wang1, Jorryt Tichelaar1,2,3, Louis R Pasquale4,5, Lucy Q Shen6, Michael V Boland7, Sarah R Wellik8, Carlos Gustavo De Moraes9, Jonathan S Myers10, Pradeep Ramulu7, MiYoung Kwon11, Osamah J Saeedi12, Hui Wang1,13, Neda Baniasadi1, Dian Li1, Peter J Bex14, Tobias Elze1,15. 1. Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston. 2. Donders Center for Medical Neuroscience, Radboud University Medical Center, Nijmegen, the Netherlands. 3. Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Nijmegen, the Netherlands. 4. Eye and Vision Research Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 5. Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 6. Massachusetts Eye and Ear, Harvard Medical School, Boston. 7. Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. 8. Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida. 9. Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York. 10. Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania. 11. Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham. 12. Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore. 13. Institute for Psychology and Behavior, Jilin University of Finance and Economics, Changchun, China. 14. Department of Psychology, Northeastern University, Boston, Massachusetts. 15. Max Planck Institute for Mathematics in the Sciences, Leipzig, Germany.
Abstract
Importance: Although the central visual field (VF) in end-stage glaucoma may substantially vary among patients, structure-function studies and quality-of-life assessments are impeded by the lack of appropriate characterization of end-stage VF loss. Objective: To provide a quantitative characterization and classification of central VF loss in end-stage glaucoma. Design, Setting, and Participants: This retrospective cohort study collected data from 5 US glaucoma services from June 1, 1999, through October 1, 2014. A total of 2912 reliable 10-2 VFs of 1103 eyes from 1010 patients measured after end-stage 24-2 VFs with a mean deviation (MD) of -22 dB or less were included in the analysis. Data were analyzed from March 28, 2018, through May 23, 2019. Main Outcomes and Measures: Central VF patterns were determined by an artificial intelligence algorithm termed archetypal analysis. Longitudinal analyses were performed to investigate whether the development of central VF defect mostly affects specific vulnerability zones. Results: Among the 1103 patients with the most recent VFs, mean (SD) age was 70.4 (14.3) years; mean (SD) 10-2 MD, -21.5 (5.6) dB. Fourteen central VF patterns were determined, including the most common temporal sparing patterns (304 [27.5%]), followed by mostly nasal loss (280 [25.4%]), hemifield loss (169 [15.3%]), central island (120 [10.9%]), total loss (91 [8.3%]), nearly intact field (56 [5.1%]), inferonasal quadrant sparing (42 [3.8%]), and nearly total loss (41 [3.7%]). Location-specific median total deviation analyses partitioned the central VF into a more vulnerable superonasal zone and a less vulnerable inferotemporal zone. At 1-year and 2-year follow-up, new defects mostly occurred in the more vulnerable zone. Initial encroachments on an intact central VF at follow-up were more likely to be from nasal loss (11 [18.4%]; P < .001). One of the nasal loss patterns had a substantial chance at 2-year follow-up (8 [11.0%]; P = .004) to shift to total loss, whereas others did not. Conclusions and Relevance: In this study, central VF loss in end-stage glaucoma was found to exhibit characteristic patterns that might be associated with different subtypes. Initial central VF loss is likely to be nasal loss, and 1 specific type of nasal loss is likely to develop into total loss.
Importance: Although the central visual field (VF) in end-stage glaucoma may substantially vary among patients, structure-function studies and quality-of-life assessments are impeded by the lack of appropriate characterization of end-stage VF loss. Objective: To provide a quantitative characterization and classification of central VF loss in end-stage glaucoma. Design, Setting, and Participants: This retrospective cohort study collected data from 5 US glaucoma services from June 1, 1999, through October 1, 2014. A total of 2912 reliable 10-2 VFs of 1103 eyes from 1010 patients measured after end-stage 24-2 VFs with a mean deviation (MD) of -22 dB or less were included in the analysis. Data were analyzed from March 28, 2018, through May 23, 2019. Main Outcomes and Measures: Central VF patterns were determined by an artificial intelligence algorithm termed archetypal analysis. Longitudinal analyses were performed to investigate whether the development of central VF defect mostly affects specific vulnerability zones. Results: Among the 1103 patients with the most recent VFs, mean (SD) age was 70.4 (14.3) years; mean (SD) 10-2 MD, -21.5 (5.6) dB. Fourteen central VF patterns were determined, including the most common temporal sparing patterns (304 [27.5%]), followed by mostly nasal loss (280 [25.4%]), hemifield loss (169 [15.3%]), central island (120 [10.9%]), total loss (91 [8.3%]), nearly intact field (56 [5.1%]), inferonasal quadrant sparing (42 [3.8%]), and nearly total loss (41 [3.7%]). Location-specific median total deviation analyses partitioned the central VF into a more vulnerable superonasal zone and a less vulnerable inferotemporal zone. At 1-year and 2-year follow-up, new defects mostly occurred in the more vulnerable zone. Initial encroachments on an intact central VF at follow-up were more likely to be from nasal loss (11 [18.4%]; P < .001). One of the nasal loss patterns had a substantial chance at 2-year follow-up (8 [11.0%]; P = .004) to shift to total loss, whereas others did not. Conclusions and Relevance: In this study, central VF loss in end-stage glaucoma was found to exhibit characteristic patterns that might be associated with different subtypes. Initial central VF loss is likely to be nasal loss, and 1 specific type of nasal loss is likely to develop into total loss.
Authors: Ilana Traynis; Carlos G De Moraes; Ali S Raza; Jeffrey M Liebmann; Robert Ritch; Donald C Hood Journal: JAMA Ophthalmol Date: 2014-03 Impact factor: 7.389
Authors: Tobias Elze; Louis R Pasquale; Lucy Q Shen; Teresa C Chen; Janey L Wiggs; Peter J Bex Journal: J R Soc Interface Date: 2015-02-06 Impact factor: 4.118
Authors: Christopher Kai Shun Leung; Shu Liu; Robert N Weinreb; Gilda Lai; Cong Ye; Carol Yim Lui Cheung; Chi Pui Pang; Kwok Kay Tse; Dennis Shun Chiu Lam Journal: Ophthalmology Date: 2011-04-29 Impact factor: 12.079
Authors: John L Keltner; Chris A Johnson; Kimberly E Cello; Mary A Edwards; Shannan E Bandermann; Michael A Kass; Mae O Gordon Journal: Arch Ophthalmol Date: 2003-05
Authors: Ricardo Y Abe; Alberto Diniz-Filho; Vital P Costa; Carolina P B Gracitelli; Saif Baig; Felipe A Medeiros Journal: Ophthalmology Date: 2015-12-15 Impact factor: 12.079
Authors: Brian C Stagg; Joshua D Stein; Felipe A Medeiros; Barbara Wirostko; Alan Crandall; M Elizabeth Hartnett; Mollie Cummins; Alan Morris; Rachel Hess; Kensaku Kawamoto Journal: Ophthalmol Glaucoma Date: 2020-08-15
Authors: Elena Solli; Hiten Doshi; Tobias Elze; Louis Pasquale; Michael Wall; Mark Kupersmith Journal: Transl Vis Sci Technol Date: 2022-01-03 Impact factor: 3.048
Authors: Wendy W Liu; Michael McClurkin; Edem Tsikata; Pui-Chuen Hui; Tobias Elze; Ali R C Celebi; Ziad Khoueir; Ramon Lee; Eric Shieh; Huseyin Simavli; Christian Que; Rong Guo; Johannes de Boer; Teresa C Chen Journal: J Glaucoma Date: 2020-10 Impact factor: 2.290
Authors: Bettina Teng; Dian Li; Eun Young Choi; Lucy Q Shen; Louis R Pasquale; Michael V Boland; Pradeep Ramulu; Sarah R Wellik; Carlos Gustavo De Moraes; Jonathan S Myers; Siamak Yousefi; Thao Nguyen; Yuying Fan; Hui Wang; Peter J Bex; Tobias Elze; Mengyu Wang Journal: Transl Vis Sci Technol Date: 2020-11-17 Impact factor: 3.048